All products are for laboratory research purposes only. Not for human consumption.
Compound guide
Copper Peptides and GHK-Cu
GHK-Cu is the most heavily researched compound in this catalogue and the only one with decades of independent human skin data behind it. It is also widely misunderstood, largely because the copper is not incidental to it.
The short version
- GHK is a three-amino-acid peptide — glycine, histidine, lysine — first isolated from human plasma in 1973.
- The copper is part of the molecule, not an additive. GHK binds copper(II) with high affinity, and most of the reported activity is attributed to the complex.
- Plasma levels fall with age, from roughly 200 ng/mL at 20 to around 80 ng/mL by 60 in the commonly cited figures.
- The sequence occurs inside collagen, in the alpha-2(I) chain, and is thought to be released when tissue is damaged.
- It has decades of cosmetic use behind it, which is why human skin data exists for GHK-Cu and not for most research peptides.
- It is not a licensed medicine anywhere, and is supplied here for laboratory research only.
The research
What published work on GHK-Cu covers
Descriptions of published research activity and findings. Nothing here is a claim about what this product does, or a statement that it is safe or effective for any purpose.
A signal released by damaged tissue
The GHK sequence sits within the alpha-2(I) chain of type I collagen. The proposal, put forward by Maquart and colleagues in the 1980s, is that when injury activates proteolytic enzymes the fragment is liberated at the wound site, where it binds copper and acts as a local repair signal.3 That framing — a molecule the body already makes, released by damage — is why GHK is described as a biological signal rather than a drug.
Collagen and the extracellular matrix
The most-replicated finding is that GHK-Cu increases production of collagen and other matrix components in fibroblast culture. Published work reports stimulation at picomolar to nanomolar concentrations, with the effect described as increasing collagen synthesis substantially at around 10 to the minus 9 molar.12 Related work reports effects on glycosaminoglycans and on the small proteoglycan decorin, and on the balance between matrix metalloproteinases and their inhibitors — that is, on both building matrix and breaking it down.
Why the copper matters
GHK on its own and GHK-Cu are not interchangeable in the literature. Copper is a required cofactor for lysyl oxidase, the enzyme that cross-links collagen and elastin, and for superoxide dismutase. The prevailing interpretation is that GHK acts partly as a delivery vehicle, carrying copper to where it is needed at concentrations that free copper ions could not safely reach.1 This is also the practical reason GHK-Cu behaves differently in solution from the other peptides in this catalogue.
Gene expression work
The most-cited modern paper analysed GHK against the Broad Institute Connectivity Map and reported that it shifted expression of a large proportion of human genes, with the authors describing effects on DNA repair, antioxidant and anti-inflammatory pathways.1 Findings from expression-profiling databases are hypothesis-generating rather than confirmatory, and the paper should be read as mapping where to look next rather than as establishing a clinical effect.
What is not established
GHK-Cu has never been through the kind of large randomised trial that licences a medicine, and it is not approved as one anywhere. Most of the human evidence comes from cosmetic and dermatological use, which is a lower evidentiary bar than clinical approval. Copper complexes also behave differently in solution from simple peptides, and no stability data has been published for GHK-Cu co-formulated with other peptides — which is directly relevant to the GLOW and KLOW blends.
References
- 1Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. Int J Mol Sci (2018). PMC6073405
- 2GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. Biomed Res Int (2015). PMC4508379
- 3The human tri-peptide GHK and tissue remodeling. J Biomater Sci Polym Ed (2008). PMID 18644225
Links open the record on PubMed or PubMed Central. These are citations to published research, not claims about this product.
Common questions
What is GHK-Cu?
GHK-Cu is a complex of the tripeptide glycyl-L-histidyl-L-lysine with a copper(II) ion. The peptide was first isolated from human plasma in 1973. The sequence also occurs within type I collagen, and the prevailing hypothesis is that it is released when tissue is damaged and acts as a local repair signal.
Is GHK the same as GHK-Cu?
No, and the distinction matters when reading the literature. GHK is the bare tripeptide; GHK-Cu is that peptide bound to copper. Copper is a required cofactor for lysyl oxidase and superoxide dismutase, and much of the reported activity is attributed to the complex rather than to the peptide alone.
Why is GHK-Cu blue?
The colour comes from the copper(II) ion, not the peptide. A blue tint in a reconstituted GHK-Cu solution is expected and is not a sign of contamination. Colour is not a purity assay either way — the batch Certificate of Analysis is.
Does GHK-Cu have more evidence than other research peptides?
Yes, in a specific sense. GHK-Cu has been used in cosmetic formulations for decades, so human skin data exists for it that does not exist for most compounds in this category. That is still a lower evidentiary bar than the randomised clinical trials required to licence a medicine, and GHK-Cu is not approved as one anywhere.
How does GHK-Cu differ from BPC-157 or TB-500?
Different molecules, different research areas and very different evidence bases. GHK-Cu research concentrates on the extracellular matrix and has independent human skin data. BPC-157 and TB-500 research concentrates on soft-tissue repair in rodent models, with no completed human trials for either. All three appear together in the GLOW and KLOW blends, though no study has tested those combinations.